AstraZeneca offloads remaining anaesthetic rights to Aspen

Josh White Sharecast | 14 Sep, 2017 07:54 - Updated: 07:54 | | |

astrazeneca
  • 4,912.00
  • 3.01%143.50
  • Max: 4,954.50
  • Min: 4,772.50
  • Volume: 3,601,094
  • MM 200 : n/a
17:20 22/09/17
  • 7,310.64
  • 0.64%46.74
  • Max: 7,320.28
  • Min: 7,242.23
  • Volume: 0
  • MM 200 : n/a
17:18 22/09/17
  • 3,443.31
  • 0.85%28.87
  • Max: 3,449.89
  • Min: 3,409.18
  • Volume: 0
  • MM 200 : n/a
17:30 22/09/17
  • 1,505.23
  • 0.01%0.17
  • Max: 1,507.81
  • Min: 1,501.34
  • Volume: 0
  • MM 200 : n/a
17:25 22/09/17
  • 13,020.17
  • 1.37%175.93
  • Max: 13,108.57
  • Min: 12,817.57
  • Volume: 0
  • MM 200 : n/a
17:30 22/09/17
  • 4,060.47
  • 0.62%25.05
  • Max: 4,064.51
  • Min: 4,022.98
  • Volume: 0
  • MM 200 : n/a
17:30 22/09/17
  • 4,008.86
  • 0.60%23.81
  • Max: 4,012.81
  • Min: 3,973.08
  • Volume: 0
  • MM 200 : n/a
17:25 22/09/17

AstraZeneca has entered into an agreement with Aspen Global Incorporated - part of the Aspen Group - under which AGI will now acquire the residual rights to the established anaesthetic medicines Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest, it announced on Thursday.

The FTSE 100 drugmaker had already entered into an agreement with AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US.

“AstraZeneca, AGI and patients have all benefitted from the successful commercial agreement we established last year,” said AstraZeneca’s executive vice president of global product and portfolio strategy, Mark Mallon.

“As our relationship has evolved, AGI has shown that it is in a strong position to maximise the value and reach of the anaesthetic medicines through its extensive commercial network.

“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas.”

Under the terms of the new agreement, AGI will now acquire the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines for an upfront consideration of $555m.

Additionally, AGI would pay AstraZeneca up to $211m in performance-related milestones based on sales and gross margin during the period from 1 September 2017 to 30 November 2019.

AstraZeneca would continue to manufacture and supply the medicines to AGI during a transition period of up to five years.

“This second transaction allows AGI to reap the additional benefits from the excellent strategic acquisition that the anaesthetics portfolio has proven to be for Aspen and a key part of this will be to continue leveraging the strong working relationship that AGI has developed with AstraZeneca,” commented Aspen group chief executive Stephen Saad.

More news

17:49 Europe close: Stocks finish higher on strong PMI readings

Stocks on the Continent finished mostly higher on the back of strong survey readings on the euro area's manufacturing and services sector and ahead of the German general elections at the weekend, although fresh barbs from Pyongyang were a drag on sentiment.

17:34 Thousands of steel workers protest ThyssenKrupp merger in Germany

Thousands of steel workers gathered in Western Germany on Friday to protest the proposed merger of ThyssenKrupp and Tata Steel's European operations which was expected to result in approximately 4,000 job losses.

17:27 London Close: FTSE firmer as pound losses ground after May speech

London stocks had reversed earlier losses to trade a little higher by Friday's close, helped along by a weaker pound as investors weighed up a key speech by Prime Minister Theresa May.

17:08 JP Morgan Chase to establish global headquarters in Warsaw

Polish Deputy Prime Minister Mateusz Morawiecki announced on Friday that US bank JP Morgan Chase had picked Warsaw to play host to its new global operations centre, bringing thousands of jobs to the region from the beginning of 2018.

17:08 FTSE 250 movers: Pets at Home dashes higher, oilers also lifted

The FTSE 250 index was on the front foot on Friday, led by retailer Pets at Home and a group of oil-related companies.

16:56 Theresa May calls for post-Brexit transition period, new security treaty

In a speech in Florence on Friday, Prime Minister Theresa May confirmed that she wanted a two-year "implementation period" post-Brexit and a new treaty with the European Union on security and justice.

15:54 FTSE 100 movers: Johnson Matthey rallies again but Smiths drops on results

London's FTSE 100 was up 0.6% to 7,305.66 in afternoon trade on Friday as investors mulled over PM Theresa May's Brexit speech in Florence.

15:39 Results round-up

Saga, the specialist provider of products and services for those over 50, reported solid growth of 5.5% in underlying profits before tax for the first half as it ordered a second new cruise ship amid high demand.

15:32 US economy shows resilience in face of hurricanes - Markit

Business activity in the US picked up in September despite hurricanes Harvey and Irma, as growth in the manufacturing sector helped to offset an easing in services, according to preliminary data released on Friday.

15:25 Thalassa suspends share buyback as FairfieldNodal commences due diligence

Thalassa Holdings confirmed the suspension of its share buyback programme on Friday, as a suitor continued to circle the marine geoscience and subsea robotics company.